• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

    10/18/24 11:59:53 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TVTX alert in real time by email
    SC 13G/A 1 Travere_Therapeutics_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    TRAVERE THERAPEUTICS INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    89422G107

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    89422G107 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,515,141

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,736,696

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,736,696.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.6%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    89422G107 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      TRAVERE THERAPEUTICS INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      3611 VALLEY CENTRE DRIVE SUITE 300 SAN DIEGO CA 92130 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      89422G107

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    89422G107 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 2,736,696.00  
      (b) Percent of class: 3.6%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 2,515,141
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 2,736,696
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ý
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    89422G107 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $TVTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TVTX

    DatePrice TargetRatingAnalyst
    1/10/2025Overweight
    Cantor Fitzgerald
    10/21/2024$9.00 → $27.00Equal Weight → Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    9/9/2024$25.00Neutral → Buy
    Guggenheim
    3/27/2024Buy → Neutral
    Guggenheim
    12/5/2023$7.00 → $10.00Neutral → Buy
    Citigroup
    11/20/2023$7.00Neutral
    Citigroup
    9/22/2023$24.00 → $8.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $TVTX
    Financials

    Live finance-specific insights

    See more
    • Travere Therapeutics Reports First Quarter 2025 Financial Results

      Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 U.S. net product sales of FILSPARI totaled $55.9 million in 1Q 2025; 703 new PSFs received in the period FILSPARI was recently converted to full approval for the treatment of IgAN in Europe and the UK Clinical data presented at the National Kidney Foundation Spring Clinical Meetings reinforced FILSPARI's foundational position in IgAN and potential in FSGS Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $322 million Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its first quarter 2025 financial results and provided a corporate update. "As the only fully approve

      5/1/25 4:01:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Report First Quarter 2025 Financial Results

      Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company

      4/24/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics,

      2/13/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    SEC Filings

    See more
    • Travere Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Travere Therapeutics, Inc. (0001438533) (Filer)

      5/16/25 4:13:55 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Travere Therapeutics, Inc. (0001438533) (Filer)

      5/15/25 4:29:26 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Travere Therapeutics Inc.

      SCHEDULE 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      5/15/25 6:18:37 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Travere Therapeutics

      Cantor Fitzgerald initiated coverage of Travere Therapeutics with a rating of Overweight

      1/10/25 9:14:01 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Travere Therapeutics from Equal Weight to Overweight and set a new price target of $27.00 from $9.00 previously

      10/21/24 8:16:27 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Travere Therapeutics

      Scotiabank initiated coverage of Travere Therapeutics with a rating of Sector Outperform

      10/16/24 8:39:33 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

      PDUFA target action date of January 13, 2026 If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026, and has indicated that it is currently planning to hold an advisory committee meeting to discuss the application. "Today marks

      5/15/25 4:05:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

      – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4'24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica's candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceutical – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRC

      5/13/25 4:05:00 PM ET
      $TVTX
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on May 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 35,900 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date

      5/12/25 5:00:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Williams Brinkley Ruth was granted 6,500 shares, increasing direct ownership by 34% to 25,750 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/16/25 7:00:22 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Poole Sandra was granted 6,500 shares, increasing direct ownership by 28% to 30,000 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/16/25 7:00:18 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orwin John A was granted 6,500 shares, increasing direct ownership by 23% to 35,375 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/16/25 7:00:16 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

      SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 5:13:38 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Travere Therapeutics Inc.

      SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 1:01:01 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

      SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 9:46:28 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

      Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm

      7/11/22 8:00:00 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

      Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

      3/23/22 7:30:00 AM ET
      $ATRA
      $NTRA
      $TVTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

      SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics

      1/4/22 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care